SGI
CSTL icon

Summit Global Investments’s Castle Biosciences CSTL Stock Holding History

Summit Global Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$337K Buy
13,718
+1,353
+11% +$44.3K 0.02% 397
2025
Q4 		$481K Buy
12,365
+13
+0.1% +$419 0.03% 325
2025
Q3 		$281K Sell
12,352
-3,297
-21% -$67K 0.02% 406
2025
Q2 		$320K Sell
15,649
-14,991
-49% -$278K 0.02% 381
2025
Q1 		$613K Buy
30,640
+2,164
+8% +$53.6K 0.04% 261
2024
Q4 		$759K Sell
28,476
-1,965
-6% -$59.8K 0.05% 272
2024
Q3 		$868K Buy
30,441
+6,629
+28% +$169K 0.06% 259
2024
Q2 		$518K Buy
+23,812
New +$531K 0.03% 339

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Global Investments's CSTL Position: Q1 2026 in Review

Summit Global Investments increased its Castle Biosciences (CSTL) stake by 11% in Q1 2026, buying an estimated $44.3K and bringing the position to 13,718 shares worth $337K. The position accounts for 0.02% of the portfolio, ranked #397.

Summit Global Investments first reported a position in CSTL in Q2 2024 and has held it in 8 quarters since. The position peaked at $868K in Q3 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Summit Global Investments held 13,718 shares of Castle Biosciences worth $337K as of Q1 2026.
  • Summit Global Investments bought 1,353 Castle Biosciences shares in Q1 2026, an estimated $44.3K.
  • Castle Biosciences made up 0.02% of Summit Global Investments's portfolio in Q1 2026, its #397 holding.
  • Summit Global Investments first reported a position in Castle Biosciences in Q2 2024 and has held it in 8 quarters since.
  • Summit Global Investments's Castle Biosciences position peaked at $868K in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Summit Global Investments's 13F filing for Q1 2026, filed 7 May 2026.